Zus Health said it raised $33 million in Series B funding as it expands a healthcare technology platform built to combine fragmented clinical information into a unified, continuously updated patient record. The company pulls data from EHR networks, pharmacies, laboratories and other healthcare sources, then uses AI to generate patient summaries and help clinicians find relevant information.
Drive Capital led the round, with participation from Sanofi Ventures, HealthX Ventures, Alumni Ventures, Andreessen Horowitz, F-Prime, Maverick Ventures and JAZZ Venture Partners. Zus said it has now raised more than $100 million in total. Founder and CEO Jonathan Bush framed the company’s goal as building a networked medical record that lets information move with the patient rather than remain trapped in siloed systems.
Where The Capital Is Going
Zus said the new financing will be used to invest in AI-powered clinical intelligence, expand its national healthcare data network and enable additional workflows for value-based care, specialty care and other areas. That mix matters because it shows the company is not pitching AI as a standalone product. Its bet is that connected data infrastructure is the prerequisite for software that clinicians can use inside care delivery.
Drive Capital general partner Molly Bonakdarpour made that point directly, saying healthcare’s AI shift depends on reliable, connected patient information. The investment case, then, is less about headline AI claims and more about whether Zus can become part of the data plumbing that other applications depend on.
Scale And Network Ambition
The company pointed to growth metrics from its platform. In just August, Zus said its network supported more than 110 million networked transactions. It also said the platform generated 39 million evidence citations year-to-date across its solutions.
Those figures suggest Zus is trying to prove both throughput and utility: one metric for how much information moves through the network, another for how often its tools surface supporting information in workflows. Its named customers and partners include Homeward Health and Circadian Health.
Zus also announced plans to pursue Qualified Health Information Network status in August 2026. That would allow the company to participate in nationwide health information exchange under the Trusted Exchange Framework and Common Agreement, a step that could strengthen its position if national exchange becomes a more important basis for platform adoption.
The strategic signal from this round is that investors still see room for companies selling interoperability as an operating layer for AI-enabled care, not just as a compliance function. If Zus can translate connected records into workflows for value-based and specialty care, its differentiation may come from making data exchange clinically actionable rather than merely available.



